Clinical evaluation of opioid use disorder treatment funded by $5.6M NIH grant
Biopharmaceutical company Aptinyx Inc. announced the finalization of a $5.6 million NIH grant for the development of a novel therapeutic for the treatment of opioid use disorder.According to a release from Aptinyx, the grant will arrive through the Helping to End Addiction Long-term (HEAL) Initiative and administered by NIDA supporting the development of NYX-783, an NMDA receptor positive
Source: healio.com